NewTimeSpace News:As of 13:58 on March 17, 2026, the CSI All-Share Pharmaceutical and Health Care Index (000991) rose 0.79%. Its constituent stocks saw notable gains, with 3S Bio Inc. up 7.50%, Shenzhen Salubris Pharmaceuticals Co., Ltd. up 5.65%, Xizang Haisco Pharmaceutical Group Co., Ltd. up 4.52%, Zejing Pharmaceutical Co., Ltd. up 4.31% and Sichuan BaiLi TianHeng Pharmaceutical Co., Ltd. up 4.05%. GF CSI All Share Health Care Index ETF(159938) rose 0.62% to RMB 0.65 per share. In the long run, as of March 16, 2026, the ETF had a cumulative increase of 1.10% in the past week. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, the ETF recorded an intraday turnover rate of 0.51% and a trading volume of RMB 26.2756 million. As of March 16, it had an average daily trading volume of RMB 54.3537 million in the past year.

In terms of scale, the latest scale of the ETF reached RMB 5.113 billion. (Data source: Wind)

In terms of capital inflows, the latest capital inflows and outflows of the ETF were balanced. Over the past 10 trading days, it had a total net capital inflow of RMB 12.4434 million. (Data source: Wind)

Data showed that leveraged funds have continued to build positions in the ETF. The latest margin purchase volume of the ETF stood at RMB 2.1327 million, with the latest margin balance reaching RMB 27.4352 million. (Data source: Wind)

As of March 16, the net asset value (NAV) of the ETF had risen 2.46% in the past year. In terms of profitability, as of March 16, 2026, since its establishment, the ETF had achieved a maximum monthly return of 22.34%, a longest consecutive monthly gain of 8 months with a cumulative increase of 67.34%, and a ratio of rising to falling months of 72:63, with an average monthly return of 5.58% in rising months. As of March 16, 2026, the ETF had an annualized excess return of 1.29% over the benchmark since its inception.

In terms of drawdown, as of March 16, 2026, the ETF had a relative drawdown of 0.05% against the benchmark since the start of the year.

In terms of fees, the management fee rate of the ETF was 0.50% and the custodian fee rate was 0.10%.

In terms of tracking accuracy, as of March 16, 2026, the ETF had a tracking error of 0.009% in the past month.

From the valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI All-Share Pharmaceutical and Health Care Index tracked by the ETF was only 32.62 times, at the 13.55% quantile of the past year. This means the valuation was lower than that in more than 86.45% of the time in the past year, standing at a historically low level.

The ETF closely tracks the CSI All-Share Pharmaceutical and Health Care Index. The CSI All-Share Industry Select Index Series selects listed companies that meet certain liquidity and market capitalization screening criteria from the CSI All-Share Industries as index samples, so as to reflect the overall performance of the securities of representative and investable listed companies in various industries.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI All-Share Pharmaceutical and Health Care Index (000991) were Jiangsu Hengrui Medicine Co., Ltd., WuXi AppTec Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Yunnan Baiyao Group Co., Ltd., Aier Eye Hospital Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Zhejiang NHU Company Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd., with the total weight of the top 10 stocks accounting for 39.02%. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

Zhongtai Financial International stated that the Government Work Report of the 4th Session of the 14th National People's Congress pointed out that China should accelerate the development of commercial health insurance, promote the high-quality development of innovative drugs and medical devices, and better meet the diversified medical and medication needs of the people. The central government has listed biomedicine as an emerging pillar industry for the first time, and it is expected to strongly support the development of the biomedicine industry in the future.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.